Combination of arsenicum trioxide and all trans retinoic acid in the treatment of relapsed acute promyelocytic leukemia
From 2001 to 2013 eleven patients with relapsed acute promyelocytic leukemia (APL) (median age – 30 years) received arsenicum trioxide (ATO). ATO was administered as a 2nd line relapse therapy in 9 patients, as 1st line relapse therapy in 2 patients. ATO was administered in a dose of 0.1 mg/kg in 7...
Saved in:
| Main Authors: | A. N. Sokolov, E. N. Parovichnikova, V. V. Troitskaya, L. A. Kuzmina, V. G. Savchenko |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2015-06-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/140 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide
by: Uday Kulkarni, et al.
Published: (2020-04-01) -
Characteristics and Outcomes of Patients with Acute Promyelocytic Leukemia: A Single-center Experience
by: Sema Seçilmiş, et al.
Published: (2025-08-01) -
Efficiency of therapy for acute promyelocytic leukemia in children, by using all-trance retinoic acid, cytosine arabinoside, and smaller-dose anthracyclines
by: E. V. Samochatova, et al.
Published: (2022-11-01) -
Basophils in Acute Promyelocytic Leukemia: Clonality or Reactiveness?
by: Xue Li, et al.
Published: (2025-06-01) -
Multiplex metabolic engineering of yeast for high-efficiency all-trans-retinoic acid production
by: Wenhao Li, et al.
Published: (2025-07-01)